Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.2K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.

Antiviral research·2026
Same author

CD16<sup>+</sup> γδ T cells and antibody-dependent cellular cytotoxicity: a new axis of immune control in hepatitis B virus infection?

Gut·2026
Same author

Searching for immune correlates in Lassa vaccine development - workshop report.

NPJ vaccines·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2026
Same author

Recovery of HBV-specific B cell function after discontinuation of nucleos(t)ide analogue therapy: new insight and future challenges.

Gut·2026
Same author

Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues.

Nature immunology·2025

Related Experiment Video

Updated: Feb 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

T-cell therapy for chronic viral hepatitis.

Antonio Bertoletti1, Anthony Tanoto Tan2, Sarene Koh3

  • 1Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore; Viral Hepatitis Laboratory, Singapore Institute for Clinical Sciences, A*STAR, Singapore.

Cytotherapy
|August 30, 2017
PubMed
Summary

Curative therapies for hepatitis B virus (HBV) infection are not yet available, unlike for hepatitis C virus (HCV). T-cell therapy is being developed to control HBV, offering potential antiviral efficiency but also risks for patients.

Keywords:
HBVHCVimmunotherapy

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.8K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Related Experiment Videos

Last Updated: Feb 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.8K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.5K

Area of Science:

  • Immunology and Virology
  • Hepatology
  • Cellular Therapy

Background:

  • Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections affect 500 million people globally, causing chronic liver disease, cirrhosis, and hepatocellular carcinoma.
  • Unlike HCV, which has high cure rates with direct-acting antivirals, curative therapies for HBV are not yet available, with current treatments only partially suppressing viral replication.
  • HBV infections are characterized by profound quantitative and functional defects in virus-specific T-cell responses, making them a target for immunotherapies.

Purpose of the Study:

  • To review the development of T-cell therapy for chronic hepatitis B virus (HBV) infection.
  • To highlight the potential antiviral efficiency of T-cell therapy against HBV.
  • To discuss the potential toxicities associated with T-cell therapy in different chronic HBV patient groups.

Main Methods:

  • Review of existing literature on T-cell therapy development for HBV.
  • Analysis of the mechanisms of T-cell dysfunction in chronic HBV.
  • Evaluation of the potential efficacy and safety profiles of T-cell-based immunotherapies.

Main Results:

  • T-cell therapy shows potential for controlling HBV replication by restoring anti-host immune responses.
  • Significant defects in virus-specific T-cell frequency and function are observed in chronic HBV patients.
  • Potential toxicities of T-cell therapy need careful consideration across different patient populations.

Conclusions:

  • T-cell therapy represents a promising avenue for achieving functional cure or sustained control of HBV infection.
  • Further research is needed to optimize T-cell therapy strategies and mitigate potential risks.
  • The development of T-cell therapy for HBV is crucial given the lack of curative treatments.